Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Journal of Clinical Oncology

Volumn 32, Issue 29, 2014, Pages 3299-3306

  Chawla, Sant P ^a   Cranmer, Lee D ^e   Van Tine, Brian A ^f   Reed, Damon R ^g   Okuno, Scott H ^h   Butrynski, James E ⁱ   Adkins, Douglas R ^f   Hendifar, Andrew E ^b   Kroll, Stew ^c   Ganjoo, Kristen N ^d  

^a Sarcoma Oncology Center   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Threshold Pharmaceuticals   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h MAYO CLINIC   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; DACARBAZINE; DOXORUBICIN; EVOFOSFAMIDE; GEMCITABINE; IFOSFAMIDE; PAZOPANIB; ANTINEOPLASTIC AGENT; NITROIMIDAZOLE DERIVATIVE; PHOSPHORAMIDE MUSTARD; PRODRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ALOPECIA; ANEMIA; ANGIOSARCOMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISTANT METASTASIS; DIZZINESS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FIBROSARCOMA; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMORRHOID; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; INDUCTION CHEMOTHERAPY; INSOMNIA; LEIOMYOSARCOMA; LIMB PAIN; LIPOSARCOMA; LIVER METASTASIS; LUNG METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OROPHARYNX PAIN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SARCOMA; SENSORY NEUROPATHY; SKIN TOXICITY; SOFT TISSUE SARCOMA; STOMATITIS; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNCLASSIFIED SARCOMA; WEIGHT REDUCTION; CLINICAL TRIAL; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; PRODRUGS; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84907515188     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.3660     Document Type: Article

References (30)

1. Eriksson M: Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol 21:vii270-vii276, 2010
2. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2, 185 patients treated with anthracyclinecontaining first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17:150-157, 1999
3. Karavasilis V, Seddon BM, Ashley S, et al: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112:1585-1591, 2008
4. Sleijfer S, Ouali M, van Glabbeke M, et al: Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 46:72-83, 2010
5. Riedel RF: Systemic therapy for advanced soft tissue sarcomas: Highlighting novel therapies and treatment approaches. Cancer 118:1474-1485, 2012
6. American Cancer Society: Cancer Facts & Figures 2008. Atlanta, GA, American Cancer Society, 2008
7. Lorigan P, Verweij J, Papai Z, et al: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25:3144-3150, 2007
8. Nielsen OS, Blay JY, Judson IR, et al: Metastatic soft tissue sarcoma in adults: Prognosis and treatment options. Am J Cancer 2:211-221, 2003
9. Casali PG, Blay JY, ESMO/CONTICANET/EUROBONET Consensus Panel of experts: Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v198-v203, 2010
10. Kerbusch T, de Kraker J, Keizer HJ, et al: Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 40:41-62, 2001
11. Brizel DM, Rosner GL, Harrelson J, et al: Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30:635-642, 1994
12. Kaanders JH, Wijffels KI, Marres HA, et al: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066-7074, 2002
13. Brown JM, Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447, 2004
14. Shannon AM, Bouchier-Hayes DJ, Condron CM, et al: Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29:297-307, 2003
15. Vaupel P, Höckel M, Mayer A: Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9:1221-1235, 2007
16. Francis P, Namløs HM, Mü ller C, et al: Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: Hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8:73, 2007
17. Rajendran JG, Wilson DC, Conrad EU, et al: [(18) F]FMISO and [(18) F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30:695-704, 2003
18. Nordsmark M, Alsner J, Keller J, et al: Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. Br J Cancer 84:1070-1075, 2001
19. Primeau AJ, Rendon A, Hedley D, et al: The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11:8782-8788, 2005
20. Meng F, Evans JW, Bhupathi D, et al: Molecular and cellular pharmacology of the hypoxiaactivated prodrug TH-302. Mol Cancer Ther 11:740-751, 2012
21. Weiss GJ, Infante JR, Chiorean EG, et al: Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 17:2997-3004, 2011
22. Ganjoo KN, Cranmer LD, Butrynski JE, et al: A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 80:50-56, 2011
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
24. Van Glabbeke M, Verweij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
25. Judson I, Verweij J, Gelderblom H, et al: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol 15:415-423, 2014
26. Ryan CW, Schoffski P, Merimsky O, et al: PICASSO 3: A phase 3 international, randomized, double-blind, placebo-controlled study of doxorubicin (dox) plus palifosfamide (pali) vs. dox plus placebo for patients (pts) in first-line for metastatic soft tissue sarcoma (mSTS). Presented at the European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013 (abstr 3802)
27. Batchelder RM, Wilson WR, Hay MP, et al: Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1. Br J Cancer 27:S52-S56, 1996
28. Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41:73-81, 1981
29. Tannock I: Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation. Cancer Res 42:4921-4926, 1982
30. Bennewith KL, Dedhar S: Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 11:504, 2011